Navigation Links
107th Annual Meeting of American Association for Cancer Research (AACR): Bayer to Present New Data on Advancing Oncology Portfolio
Date:4/13/2016

WHIPPANY, N.J., April 13, 2016 /PRNewswire/ -- Bayer will present its latest data on investigational oncology compounds including several selective small molecule inhibitors, as well as different types of biologic compounds including an antibody, two antibody-drug conjugates, and thorium conjugates. The studies will be presented at the American Association for Cancer Research (AACR) 107th Annual Meeting, April 16-20, 2016, in New Orleans, LA.

Bayer, together with its partner organizations, will feature a total of four oral and 35 poster presentations on oncology research and early drug development.  

The following list comprises a selection of presentations on Bayer pipeline projects presented at AACR 2016.

Oral Presentations

  • CD22 Thorium Conjugate (TC): An alpha-pharmaceutical
    • Drug Development Track: Special Session – New Drugs on the Horizon 2
    • Sunday, April 17, 5:03 p.m.-5:27 p.m., New Orleans Theater C, Morial Convention Center
  • BAY 1436032: An orally available inhibitor of mutant forms of IDH1
    • Minisymposium; Abstract# 2645
    • Monday, April 18, 4:05 p.m.-4:20 p.m., New Orleans Theater A, Morial Convention Center
  • Discovery of BAY 1163877 – A pan-FGFR inhibitor: De novo structure-based design and lead optimization of benzothiophenyl-pyrrolotriazines
    • Minisymposium – Drug Design and Delivery; Abstract# 4332
    • Tuesday, April 19, 3:20 p.m.-3:35 p.m., Room 293, Morial Convention Center
  • Identification and optimization of GLUT-1 inhibitors
    • Minisymposium – Drug Design and Delivery; Abstract# 4333
    • Tuesday, April 19, 3:35 p.m.-3:50 p.m., Room 293, Morial Convention Center

Selected Poster Presentations

  • Allosteric AKT1/2-inhibitor BAY 1125976 in luminal breast cancer resistant to antihormone therapy
    • Poster Session: Experimental and Molecular Therapeutics – PI3K/AKT Inhibitors; Abstract# 379
    • Sunday, April 17, 1:00 p.m.-5:00 p.m., Morial Convention Center, Poster Section 19, Poster# 10
  • Preclinical mode of action and anti-tumor efficacy of the MKNK1 inhibitor BAY 1143269 in NSCLC models
    • Poster Session: Experimental and Molecular Therapeutics – Novel Antitumor Agents; Abstract# 341
    • Sunday, April 17, 1:00 p.m.-5:00 p.m., Morial Convention Center, Poster Section 17, Poster# 22
  • BAY 1187982, an FGFR2-ADC in a diffuse type gastric cancer patient-derived xenograft model with acquired resistance to pan-FGFR inhibitor AZD4547
    • Late-Breaking Poster Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1; Abstract# LB-117
    • Monday, April 18, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 11, Poster# LB-117
  • A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)
    • Poster Session: Phase II/III Clinical Trials in Progress; Abstract# CT083
    • Tuesday, April 19, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 13, Poster# CT083
  • A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2
    • Poster Session: Phase II/III Clinical Trials in Progress; Abstract# CT084
    • Tuesday, April 19, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 13, Poster# CT084
  • Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL):  CHRONOS-3 and CHRONOS-4
    • Poster Session: Phase II/III Clinical Trials in Progress; Abstract# CT085
    • Tuesday, April 19, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 13, Poster# CT085
  • BAY 1143572, an orally available inhibitor of PTEFb/CDK9 currently in Phase I, in preclinical models of acute myeloid leukemia (AML)
    • Poster Session: Experimental and Molecular Therapeutics – Novel Targets and Pathways; Abstract# 3022
    • Tuesday, April 19, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 17, Poster# 12
  • Second generation 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: development of BAY 1082439, a balanced PI3Kα / PI3Kβ inhibitor
    • Poster Session: Cancer Chemistry – Drug Design; Abstract# 4851
    • Wednesday, April 20, 8:00 a.m.-12:00 p.m., Morial Convention Center, Poster Section 21, Poster# 16

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.

Forward Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

PP-910-US-0367

Intended for U.S. Media Only

Logo - http://photos.prnewswire.com/prnh/20140312/NY79226LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/107th-annual-meeting-of-american-association-for-cancer-research-aacr-bayer-to-present-new-data-on-advancing-oncology-portfolio-300250758.html


'/>"/>
SOURCE Bayer Corporation
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
3. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
4. Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
7. Hill-Rom to Participate in the 38th Annual Deutsche Bank Health Care Conference
8. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
9. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
10. Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
11. LCA-Vision Reports on Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... ... January 08, 2020 , ... ... Medicare for medication-assisted treatment services at their Opioid Treatment Programs (OTPs) across ... medications, as well as counseling, began on January 1st. All BayMark branded ...
(Date:1/7/2020)... VEGAS (PRWEB) , ... January 07, 2020 , ... ... world’s first calibration-free blood pressure (BP) sensor system for integration in hearables and ... medical device and consumer electronics manufacturers for inclusion in their products. Embedded in ...
(Date:1/7/2020)... TORONTO (PRWEB) , ... January 06, 2020 , ... Myant ... that enable continuous and ambient heart health management at CES 2020 (January 7-10, Las ... as a winner in the Health & Wellness category of the CES 2020 Innovation ...
Breaking Medicine Technology:
(Date:1/7/2020)... ... January 07, 2020 , ... ... services, today identified six trends that will significantly impact the point of care ... the time shared between a provider and patient is the most important aspect ...
(Date:1/7/2020)... ... 2020 , ... Twenty-six people, all but one who live with Young Onset ... YOPD attend the 6th World Parkinson Congress. The participants, representing 11 countries , ... all 52 weeks in 2020. The group aims to raise at least $50,000 for ...
(Date:1/7/2020)... ... January 06, 2020 , ... A December 6 ... weight loss surgery and fewer complications including high blood pressure and premature birth before ... between their first and their second pregnancies were less likely to suffer adverse pregnancy ...
(Date:1/5/2020)... ... ... NJ Top Dentist, Dr. Irvin B. Sherman has been reviewed and approved ... teens and the special needs patient. The practice is located in Avon and Manasquan, ... Dr. Sherman and his practice will be addressing issues that mothers are having with ...
(Date:1/3/2020)... ... 2020 , ... Liz Barlowe, MA, CMC was recently elected ... Life Care Professionals® have advanced degrees and are experts in health and human ... with the family to provide recommendations for needed goods and services to enhance ...
Breaking Medicine News(10 mins):